Your browser is no longer supported. Please, upgrade your browser.
Settings
ATOS Atossa Genetics Inc. daily Stock Chart
ATOS [NASD]
Atossa Genetics Inc.
Index- P/E- EPS (ttm)-2.42 Insider Own0.31% Shs Outstand9.46M Perf Week-1.95%
Market Cap19.01M Forward P/E- EPS next Y-1.32 Insider Trans0.00% Shs Float9.08M Perf Month-6.07%
Income-16.70M PEG- EPS next Q-0.52 Inst Own2.80% Short Float3.44% Perf Quarter-2.90%
Sales- P/S- EPS this Y49.80% Inst Trans-14.52% Short Ratio0.76 Perf Half Y-54.32%
Book/sh1.85 P/B1.09 EPS next Y20.50% ROA-102.20% Target Price9.00 Perf Year11.67%
Cash/sh1.81 P/C1.11 EPS next 5Y- ROE-136.10% 52W Range0.80 - 7.39 Perf YTD97.06%
Dividend- P/FCF- EPS past 5Y46.50% ROI- 52W High-72.80% Beta3.24
Dividend %- Quick Ratio17.80 Sales past 5Y- Gross Margin- 52W Low151.25% ATR0.13
Employees2 Current Ratio17.80 Sales Q/Q- Oper. Margin- RSI (14)44.09 Volatility7.57% 5.16%
OptionableYes Debt/Eq0.01 EPS Q/Q84.30% Profit Margin- Rel Volume0.26 Prev Close2.03
ShortableYes LT Debt/Eq0.00 EarningsAug 19 AMC Payout- Avg Volume411.42K Price2.01
Recom3.00 SMA20-2.31% SMA50-4.64% SMA200-5.60% Volume106,096 Change-0.99%
Jan-26-18Initiated Maxim Group Buy $2
Sep-06-19 08:30AM  Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference GlobeNewswire
Sep-03-19 08:00AM  Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet GlobeNewswire
Aug-13-19 01:26PM  Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update GlobeNewswire
Jul-30-19 08:30AM  Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk GlobeNewswire
Jul-17-19 08:30AM  Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests GlobeNewswire
Jul-11-19 08:30AM  Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated GlobeNewswire
Jun-28-19 11:38AM  A Look At Benzinga Pro's Most-Searched Tickers For June 28, 2019 Benzinga
Jun-27-19 08:00AM  Atossa Genetics Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density GlobeNewswire +15.70%
Jun-19-19 03:56PM  Some Atossa Genetics (NASDAQ:ATOS) Shareholders Have Copped A 99% Share Price Wipe Out Simply Wall St.
May-30-19 08:00AM  Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 GlobeNewswire
May-13-19 05:21PM  Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update GlobeNewswire
Apr-30-19 06:10AM  "The Digital Economy & World Markets" ACCESSWIRE
Apr-25-19 12:00PM  Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit GlobeNewswire -8.05%
Apr-22-19 08:45AM  Reducing This Amino Acid May Aid In Fight Against Breast Cancer ACCESSWIRE +11.42%
08:30AM  Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019 GlobeNewswire
Mar-28-19 04:30PM  Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update GlobeNewswire
Mar-27-19 10:15AM  "Bull Market Hopping?" ACCESSWIRE -5.54%
Mar-26-19 08:30AM  Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient GlobeNewswire
Mar-18-19 08:30AM  Atossa Genetics Announces Receipt of $10 Million GlobeNewswire +25.36%
Mar-14-19 01:01PM  What Type Of Shareholder Owns Atossa Genetics Inc.s (NASDAQ:ATOS)? Simply Wall St. +368.21%
12:53PM  Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing InvestorPlace
08:30AM  Atossa Genetics Announces FDA Approval of Oral Endoxifen for Expanded Access as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient GlobeNewswire
Feb-27-19 06:05AM  "On Fed's Wings" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter ACCESSWIRE
Feb-07-19 08:30AM  Atossa Genetics Reports Results From Expanded Access Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues GlobeNewswire +14.09%
Feb-04-19 08:30AM  Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force GlobeNewswire
Jan-30-19 09:15AM  Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter ACCESSWIRE
Jan-28-19 08:00AM  Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019 GlobeNewswire
Jan-10-19 07:00AM  Today's Research Reports on Trending Tickers: BioTelemetry and Atossa Genetics ACCESSWIRE -10.63%
Jan-09-19 11:58AM  4 Healthcare Stocks Looking To Set January Highs ACCESSWIRE +30.08%
08:35AM  Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen GlobeNewswire
Dec-28-18 07:20AM  Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics What Drives Growth in Today's Competitive Landscape GlobeNewswire +7.98%
Dec-19-18 08:05AM  "The Roller Coaster Ride Continues" ACCESSWIRE
Dec-07-18 12:07PM  Edison issues outlook on Atossa Genetics (ATOS) GlobeNewswire
Dec-03-18 08:00AM  Atossa Genetics Announces FDA Approval  of Endoxifen for Expanded Access as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient GlobeNewswire +21.05%
Nov-21-18 08:05AM  ''A Spate of Factors'' Vista Partners November 2018 Macro Economic and Investment Newsletter ACCESSWIRE -5.51%
Nov-13-18 04:10PM  Atossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company Update GlobeNewswire +7.50%
Oct-25-18 09:10AM  Report: Exploring Fundamental Drivers Behind Atossa Genetics, Titan International, Olympic Steel, L Brands, Sysco, and TiVo New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -5.19%
Oct-18-18 04:00PM  "...Amidst Market Volatility" Vista Partners' October Macroeconomic & Investment Monthly Newsletter ACCESSWIRE
Oct-11-18 08:00AM  Atossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density GlobeNewswire
Sep-26-18 09:05AM  ''Superfirms' Domination Influences Economic Factors'' ACCESSWIRE
Sep-25-18 08:20AM  Report: Developing Opportunities within Crocs, NetApp, Gannett Co., Atossa Genetics, Omega Flex, and Lithia Motors Future Expectations, Projections Moving into 2018 GlobeNewswire
Sep-14-18 09:10AM  An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, "What Is Gynecomastia?" ACCESSWIRE -9.44%
Sep-13-18 08:00AM  Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen GlobeNewswire
Sep-12-18 08:00AM  Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT GlobeNewswire -10.78%
Aug-23-18 09:02AM  ''Robust Economy, Resilient Market'' ACCESSWIRE
Aug-21-18 09:05AM  "What Is Intraductal Immuno-oncology & CAR-T Cell Therapy?" ACCESSWIRE
Aug-13-18 04:15PM  Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update GlobeNewswire
Aug-01-18 09:05AM  The Groundwork Forum Podcast Publishes "An Overview of Breast Cancer Treatment Innovator Atossa Genetics" ACCESSWIRE
08:00AM  Atossa Genetics Contracts with Additional Manufacturer of Endoxifen GlobeNewswire
Jul-31-18 08:15AM  Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics, and McDonald's Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jul-30-18 08:30AM  Investor Expectations to Drive Momentum within NetApp, eBay, The Boeing, HCP, Atossa Genetics, and Anavex Life Sciences Discovering Underlying Factors of Influence GlobeNewswire
Jul-25-18 09:05AM  Vista Partners Publishes July's Macroeconomic & Investment Newsletter ACCESSWIRE
Jul-18-18 08:00AM  Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program GlobeNewswire
Jul-13-18 08:00AM  Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer GlobeNewswire
Jun-27-18 12:55PM  ''Strong Economy, Trade Wars & Market Volatility'' ACCESSWIRE
Jun-26-18 08:00AM  Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density GlobeNewswire
Jun-20-18 08:00AM  Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men GlobeNewswire +5.20%
Jun-14-18 08:00AM  Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board GlobeNewswire
Jun-11-18 09:24PM  Does Atossa Genetics Incs (NASDAQ:ATOS) -89.06% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
May-31-18 09:05AM  "The Balancing Act" ACCESSWIRE
May-25-18 08:00AM  Atossa Announces $13.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering GlobeNewswire
May-24-18 01:32PM  When Should You Buy Atossa Genetics Inc (NASDAQ:ATOS)? Simply Wall St.
May-15-18 08:00AM  Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men GlobeNewswire
May-14-18 04:24PM  Atossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT GlobeNewswire -6.57%
08:00AM  Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update GlobeNewswire
May-11-18 08:00AM  Atossa Genetics Supports National Women's Health Week Lead by U.S. Department of Health and Human Services Office on Womens Health GlobeNewswire
May-08-18 08:00AM  Atossa Genetics Regains NASDAQ Compliance GlobeNewswire -10.50%
May-07-18 08:15AM  Atossa Genetics Reminds Investors of Todays Deadline to be a Shareholder of Record GlobeNewswire +11.17%
May-03-18 08:15AM  Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth GlobeNewswire
May-01-18 08:10AM  Todays Research Reports on Stocks to Watch: Atossa Genetics and SteadyMed ACCESSWIRE -10.73%
Apr-30-18 08:15AM  Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study GlobeNewswire +29.97%
Apr-26-18 09:05AM  "U.S. Economy Remains Strong, Anticipating Steady Growth with Rate Twist" ACCESSWIRE -8.33%
Apr-24-18 08:15AM  Atossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men GlobeNewswire +27.09%
Apr-23-18 04:05PM  Atossa Genetics Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering GlobeNewswire -15.06%
Apr-20-18 08:15AM  Atossa Genetics Announces 1 for 12 Reverse Stock Split GlobeNewswire -19.35%
Apr-16-18 08:15AM  Atossa Genetics Requests Shareholders to Vote GlobeNewswire -12.82%
07:50AM  Report: Developing Opportunities within Ford Motor, Atossa Genetics, Paramount Group, American Airlines Group, Parsley Energy, and eBay Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-12-18 08:00AM  Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study of Male Subjects GlobeNewswire
Mar-28-18 09:05AM  "Strong Economic Growth Predicted Despite Volatile Stock Market" ACCESSWIRE -6.60%
Mar-27-18 08:30AM  Atossa Genetics Appoints Per Hall, MD, Ph.D. as Scientific Advisor GlobeNewswire
Mar-22-18 08:00AM  Atossa Genetics Launches Mens Breast Health Program GlobeNewswire +6.73%
Mar-13-18 08:05AM  Atossa Genetics, Endoxifen Progressing, Breast Cancer, Analysts Target and Pipeline Review ACCESSWIRE -6.03%
Mar-09-18 08:10AM  Todays Research Reports on Stocks to Watch: Atossa Genetics and Jaguar Health ACCESSWIRE -21.98%
Mar-08-18 04:05PM  Atossa Genetics Announces 2017 Financial Results and Provides Company Update GlobeNewswire +18.94%
Feb-28-18 09:05AM  "Clear Skies Ahead?" ACCESSWIRE +8.55%
Feb-14-18 09:05AM  Atossa Genetic's Janet Rea Presenting On ''TRAP CAR-T and Related Cell Therapies'' at Adoptive T- Cell Therapy Symposium In San Francisco Feb. 15th ACCESSWIRE +17.35%
07:40AM  Analysis: Positioning to Benefit within NRG Energy, Foot Locker, Campbell Soup, Atossa Genetics, Gentex, and Genworth Financial Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-13-18 08:00AM  Atossa Genetics to Present at Adoptive T-Cell Therapy Symposium - Molecular Medicine Tri-Conference on Thursday February 15, 2018 GlobeNewswire +12.01%
Feb-08-18 08:25PM  Vista Partners Updates Coverage on Four Dow 30 Companies: CAT, 3M, IBM & UNH ACCESSWIRE +16.36%
Feb-02-18 01:59PM  Atossa Genetics Inc Could Have an Asset That Kills Breast Cancer Cells Faster and Improves Clinical Outcomes; Jason Kolbert Weighs In SmarterAnalyst
Feb-01-18 06:10PM  Atossa Genetics Presents Additional Findings in Breast Cancer Study - Shares Up in After Hours Trading ACCESSWIRE -12.06%
04:27PM  Biotech Movers: Atossa Genetics Inc Raises on Back of Positive Early Clinical Data in Breast Cancer SmarterAnalyst
04:01PM  Atossa Genetics Presents Additional Findings from its Phase 1 Study of Oral Endoxifen GlobeNewswire
Jan-31-18 09:15AM  "Déjà vu All Over Again?" ACCESSWIRE +48.15%
08:15AM  Atossa Genetics to Host Conference Call to Present Additional Findings from its Phase 1 Study of Oral Endoxifen Thursday February 1, 2018 at 4:30 pm EST GlobeNewswire
Jan-30-18 11:02AM  Top 3 Growth Stocks For The Month Simply Wall St. -8.47%
Jan-29-18 10:30AM  2 Stocks Taking Cues for This Year's Bull Market ACCESSWIRE +40.48%
08:00AM  Todays Research Reports on Trending Tickers: Atossa Genetics and Pulmatrix ACCESSWIRE
Jan-26-18 02:35PM  Atossa Genetics Receives Additional Sell Side Support & Coverage - Shares Surge ACCESSWIRE +29.19%
Jan-23-18 09:05AM  3 FREE Biotech/Healthcare Research Reports: Atossa Genetics Inc. (ATOS), Johnson & Johnson, Inc. (JNJ), & Pfizer Inc. (PFE) ACCESSWIRE
Atossa Genetics Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Its lead program is the development of Endoxifen, conducting two Phase II studies, which is an active metabolite of tamoxifen to treat and prevent breast cancer. The company is also developing intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. Its medical devices also include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator, which collect specimens of nipple aspirate fluid for cytological testing. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.